Long-term Follow-up Study for Patients Treated with Galapagos CAR T-cell Therapies

Sponsor: Lakefront Biotherapeutics NV

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT06652633

Provider View

This study is designed to monitor patients who have received Galapagos CAR T-cell therapies, focusing on their long-term safety and effectiveness over a period of 15 years.

Patient Parameters

Program Overview

This study aims to follow patients who have been treated with Galapagos CAR T-cell therapies for 15 years after their treatment. The goal is to ensure the long-term safety and effectiveness of these therapies. This involves checking for any delayed side effects and understanding the overall benefits and risks over time. The study will also monitor for any potential issues related to the therapy's genetic components and how long the CAR T-cells remain active in the body.

Eligibility Criteria

Inclusion Criteria

  • All patients who have received Galapagos CAR T-cell therapy in a clinical trial or through a Managed Access Program.

Exclusion Criteria

  • There are no exclusion criteria for this study

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.